Friday, 13 September 2019

Defeating deafness. We will beat it..

hearing loss drug fx-322
slowly but surely we will find a way to erase deafness.  Biotech startup, Frequency Therapeutics, today announced positive results from a Phase 1/2 safety trial to evaluate FX-322, an investigational drug candidate designed to facilitate hearing restoration.  

The trial assessed the safety of a single dose of FX-322 given by intratympanic administration in adult patients with stable sensorineural hearing loss (SSHL) who had a medical history consistent with either chronic noise exposure or idiopathic sudden sensorineural hearing loss. According to Frequency Therapeutics, FX-322 is the company’s lead Progenitor Cell Activation (PCA) candidate for hearing restoration and is described as a “proprietary combination of small molecules designed to transiently activate inner ear progenitor cells and enable the creation of new inner ear hair cells in the cochlea.” 

Positive Trial Results for Hearing Restoration Drug Candidate In the Phase 1/2 study, FX-322 was reported to be “safe and well-tolerated” following a single intratympanic injection with no serious adverse events. In addition, improvements in hearing function, including audiometry and word scores, were observed in multiple FX-322 treated patients. “Hearing loss affects millions of people and current treatments are unable to restore hearing once it is lost. 

The study results for FX-322, which show signs of functional hearing improvement, are very promising and represent an exciting step toward a potential treatment for patients.” —Susan Marenda King, M.D., Neurotologist, Ear Medical Group in San Antonio, TX and lead enroller in the clinical trial “While the focus of this study was safety, we are excited to see initial results in sensorineural hearing restoration as there are currently no treatments to restore hearing for these patients,” said David L. Lucchino, President, Co-founder and CEO of Frequency. “Furthermore, this data provides support for our small-molecule-driven regenerative medicine platform, which has the opportunity to address numerous degenerative diseases.”

No comments:

Post a comment